Market Overview

Morgan Stanley Reiterates Equal-Weight Rating on Abbott Laboratories

Share:
Related ABT
3 Companies That Could Be Negatively Impacted By Johnson & Johnson Sale Of Cordis
Mason Hawkins Likes Chemtura, Melco Crown; Doesn't Like Berkshire Hathaway
Do-It-Yourself All Sector Dividend Aristocrat Portfolio (Seeking Alpha)

In a report published Monday, Morgan Stanley reiterated its Equal-Weight rating on Abbott Laboratories (NYSE: ABT).

Morgan Stanley noted, “The critical debates on the new Abbott are: (i) feasibility of upper-single-digit growth, (ii) magnitude of operating leverage and visibility of double-digit earnings growth and (iii) whether a valuation inefficiency exists. We believe Abbott has set expectations at a fair level and is likely to hit targets for mid- to high-single-digit revenue and 10%+ EPS growth.”

Abbott Laboratories closed on Friday at $65.53.

Latest Ratings for ABT

DateFirmActionFromTo
Feb 2015JefferiesMaintainsHold
Jan 2015BarclaysMaintainsEqual-weight
Jan 2015Stifel NicolausMaintainsBuy

View More Analyst Ratings for ABT
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Reiteration Analyst Ratings

 

Related Articles (ABT)

Around the Web, We're Loving...

Get Benzinga's Newsletters